Is Jubilant Pharmova a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Jubilant Pharmova Ltd is a average quality company .

Is Jubilant Pharmova undervalued or overvalued?

The key valuation ratios of Jubilant Pharmova Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Jubilant Pharmova share price return in the past 10 years?

Jubilant Pharmova Ltd share price has appreciated 24.7% annually (CAGR) over the past ten years.

Is Jubilant Pharmova a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Jubilant Pharmova Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

Jubilant Pharmova Ltd - Stock Valuation and Financial Performance

Name: Jubilant Pharmova
Brand: Jubilant Pharmova

BSE: 530019 | NSE: JUBLPHARMA | Pharmaceuticals & Drugs | Small Cap

Place order

Jubilant Pharmova Share Price

₹1,226.50 23.15 1.92%
as on 03-Dec'24 16:59

10 Year X-Ray of Jubilant Pharmova:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	10.4%	7.1%	7.6%	13.6%	8.1%	10.1%	11.8%	4.4%	3.7%	2.6%	-
Value Creation Index ⓘ	-0.3	-0.5	-0.4	0.0	-0.4	-0.3	-0.1	-0.7	-0.7	-0.8	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	3,176	2,656	2,491	3,306	3,439	3,140	2,710	726	810	785	697
Sales YoY Gr.	-	-16.4%	-6.2%	32.7%	4%	-8.7%	-13.7%	-73.2%	11.6%	-3.1%	-
Adj EPS ⓘ	1.2	4.8	4.8	16.1	10.3	20.6	13.5	5.1	3.1	2	1.9
YoY Gr.	-	289.4%	0.2%	234.6%	-35.7%	99.4%	-34.6%	-62%	-39.8%	-33.8%	-
BVPS (₹) ⓘ	122.1	126.3	128.2	141.2	146.9	163.7	80.5	153.1	151.6	148.6	144.3
Adj Net Profit ⓘ	19.6	76.4	76.4	256	165	328	215	81.6	49.1	32.5	30
Cash Flow from Ops. ⓘ	286	164	419	558	182	317	608	-3.6	-65.1	143	-
Debt/CF from Ops. ⓘ	8	11	4.1	2.6	9.4	6.2	0.8	-49	-4.6	2.4	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-14.4%	-25.6%	-33.8%	-3.1%
Adj EPS ⓘ	5.8%	-27.7%	-46.7%	-33.8%
BVPSⓘ	2.2%	0.2%	22.7%	-2%
Share Price	24.7%	19.7%	27.1%	171%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	1.1	3.9	3.8	11.9	7.2	13.3	11	4.4	2	1.4	1.3
Op. Profit Mgn % ⓘ	8.9	11.9	13	16.4	10	12.1	15.8	1.1	0.4	2.3	1
Net Profit Mgn % ⓘ	0.6	2.9	3.1	7.7	4.8	10.5	7.9	11.2	6.1	4.1	4.4
Debt to Equity ⓘ	1.2	0.9	0.8	0.6	0.7	0.8	0.4	0.1	0.1	0.2	0.1
Working Cap Days ⓘ	216	195	154	133	139	161	102	139	250	262	123
Cash Conv. Cycle ⓘ	47	40	44	23	28	41	24	67	136	142	46

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to 1.30%

Sales growth has been subdued in last 3 years -33.84%

Net Profit has been subdued in last 3 years -46.71%

Sales growth is not so good in last 4 quarters at -5.73%

Latest Financials - Jubilant Pharmova Ltd.

	Standalone	Consolidated
TTM EPS (₹)	1.9	37.2
TTM Sales (₹ Cr.)	697	6,874
BVPS (₹.) ⓘ	144.3	373
Reserves (₹ Cr.) ⓘ	2,283	5,925
P/BV ⓘ	8.34	3.23
PE ⓘ	630.50	32.32

From the Market
52 Week Low / High (₹)	451.05 / 1309.00
All Time Low / High (₹)	3.51 / 1309.00
Market Cap (₹ Cr.)	19,167
Equity (₹ Cr.)	15.9
Face Value (₹)	1
Industry PE ⓘ	44.7

Management X-Ray of Jubilant Pharmova:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Jubilant Pharmova

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Jubilant Pharmova

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	3,176	2,656	2,491	3,306	3,439	3,140	2,709	726	810	785
Operating Expenses ⓘ	2,894	2,344	2,173	2,767	3,118	2,769	2,282	719	807	768
Manufacturing Costs	573	513	475	568	617	640	499	103	125	129
Material Costs	1,936	1,453	1,310	1,771	2,053	1,684	1,450	332	415	356
Employee Cost	241	216	226	264	266	265	221	164	167	190
Other Costs ⓘ	145	162	162	163	183	179	113	121	100	94
Operating Profit ⓘ	282	312	318	539	321	371	427	6	3	17
Operating Profit Margin (%)	8.9%	11.8%	12.8%	16.3%	9.3%	11.8%	15.8%	0.9%	0.4%	2.1%
Other Income ⓘ	106	62	52	46	78	173	48	126	138	103
Interest ⓘ	233	201	174	135	129	136	102	11	19	30
Depreciation ⓘ	107	87	81	83	86	107	100	37	43	48
Exceptional Items ⓘ	198	0	0	0	0	-2	0	0	0	0
Profit Before Tax ⓘ	246	86	115	368	183	299	273	85	79	42
Tax ⓘ	41	13	35	104	36	-22	59	4	29	10
Profit After Tax	205	73	79	263	148	321	214	80	50	32
PAT Margin (%)	6.5%	2.7%	3.2%	8.0%	4.3%	10.2%	7.9%	11.1%	6.2%	4.0%
Adjusted EPS (₹)	12.9	4.6	5.0	16.5	9.3	20.2	13.5	5.1	3.1	2.0
Dividend Payout Ratio (%)	23%	65%	60%	18%	49%	25%	37%	99%	159%	252%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	1,945	2,014	2,042	2,249	2,340	2,607	1,282	2,439	2,411	2,362
Share Capital ⓘ	16	16	16	16	16	16	16	16	16	16
Reserves ⓘ	1,929	1,998	2,026	2,233	2,324	2,591	1,267	2,423	2,395	2,346
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	2,080	1,569	1,564	1,250	1,602	1,951	493	174	302	340
Long Term Debt	1,739	1,115	1,387	1,059	1,140	1,328	420	174	174	247
Short Term Debt	340	454	177	191	463	623	73	0	128	94
Trade Payables	508	364	487	749	596	619	16	159	164	148
Others Liabilities ⓘ	709	359	288	376	325	257	53	89	115	129
Total Liabilities ⓘ	5,241	4,306	4,382	4,625	4,864	5,433	1,845	2,860	2,991	2,980
Fixed Assets
Gross Block	2,303	1,502	1,587	1,685	1,822	2,288	149	867	947	1,009
Accumulated Depreciation	857	86	166	247	331	424	22	230	260	297
Net Fixed Assetsⓘ	1,446	1,415	1,421	1,438	1,491	1,865	127	637	687	711
CWIP ⓘ	20	36	65	115	284	59	0	35	47	37
Investmentsⓘ	1,766	1,709	1,710	1,706	1,764	1,764	1,646	1,646	1,657	1,657
Inventories	516	475	454	586	492	656	0	323	314	251
Trade Receivables	319	341	386	494	481	425	0	131	189	194
Cash Equivalents	137	41	77	38	35	258	40	23	11	36
Others Assetsⓘ	1,037	288	269	248	317	406	31	66	87	94
Total Assets ⓘ	5,241	4,306	4,382	4,625	4,864	5,433	1,845	2,860	2,991	2,980

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	286	164	419	558	182	317	608	-4	-65	143
PBT ⓘ	246	86	115	368	183	299	273	85	79	42
Adjustment ⓘ	59	260	230	207	159	103	196	-49	-35	48
Changes in Working Capital ⓘ	18	-168	80	42	-112	-65	181	-3	-92	66
Tax Paid ⓘ	-38	-14	-5	-58	-49	-20	-43	-19	-17	-12
Cash Flow From Investing Activity ⓘ	1,319	522	-43	-127	-285	-198	178	93	31	-40
Capex	-79	-68	-103	-141	-281	-197	-92	-37	-59	-67
Net Investments	906	413	0	0	0	0	129	0	-9	-7
Others ⓘ	492	177	60	14	-4	-1	142	130	99	34
Cash Flow From Financing Activityⓘ	-1,647	-784	-338	-470	85	-41	-782	-107	23	-78
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	-301	-520	-156	-286	0	-160	-136	0	0	100
Interest Paid ⓘ	-245	-201	-170	-138	-134	-147	-102	-11	-18	-30
Dividend Paid ⓘ	-54	-51	-53	-55	-56	-153	-1	-80	-80	-80
Others ⓘ	-1,048	-13	41	9	275	419	-542	-16	121	-68
Net Cash Flow ⓘ	-42	-98	38	-40	-18	78	5	-18	-12	25

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	11.15	3.69	3.9	12.28	6.43	12.98	11.03	4.33	2.06	1.32
ROCE (%)	10.35	7.13	7.64	13.57	8.1	10.1	11.82	4.36	3.67	2.64
Asset Turnover Ratio	0.56	0.58	0.6	0.74	0.72	0.61	0.74	0.31	0.28	0.26
PAT to CFO Conversion(x)	1.4	2.25	5.3	2.12	1.23	0.99	2.84	-0.05	-1.3	4.47
Working Capital Days
Receivable Days	47	43	51	48	52	53	0	66	72	89
Inventory Days	68	65	65	57	57	67	0	163	143	131
Payable Days	104	110	119	127	120	132	80	96	142	161

Jubilant Pharmova Ltd Stock News

Jubilant Pharmova Ltd FAQs

What is the share price of Jubilant Pharmova?

Company share prices are keep on changing according to the market conditions. The closing price of Jubilant Pharmova on 03-Dec-2024 16:59 is ₹1,226.5.

What is the market cap of Jubilant Pharmova?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Dec-2024 16:59 the market cap of Jubilant Pharmova stood at ₹19,167.1.

What is the P/E ratio of Jubilant Pharmova?

The latest P/E ratio of Jubilant Pharmova as of 03-Dec-2024 16:59 is 630.5.

What is the P/B ratio of Jubilant Pharmova?

The latest P/B ratio of Jubilant Pharmova as of 03-Dec-2024 16:59 is 8.34.

What is the 52-week high and low of Jubilant Pharmova?

The 52-week high of Jubilant Pharmova is ₹1,309 and the 52-week low is ₹451.1.

What is the TTM revenue of Jubilant Pharmova?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Jubilant Pharmova is ₹697.2 ( Cr.) .

About Jubilant Pharmova Ltd

Jubilant Life Sciences (formerly Jubilant Organosys) was incorporated in the year 1978. It’s a public limited company domiciled in India and incorporated under the provisions of Companies Act, 1956. Its shares are listed on BSE Limited and National Stock Exchange of India Limited.

The Pharmaceuticals segment, through its wholly-owned subsidiary Jubilant Pharma Limited, is engaged in manufacturing and supply of APIs, solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six USFDA approved manufacturing facilities in the US, Canada and India and a network of various radiopharmacies in the US.

The Life Science Ingredients segment is engaged in specialty intermediates, nutritional products and life science chemicals through five manufacturing facilities in India. The drug discovery solutions business is served by Jubilant Biosys and the India branded pharmaceuticals business is an Indian venture with a range of pharmaceutical offerings for the domestic market, focusing primarily on products to treat medical conditions in the field of cardiology and diabetology.

Business area of the company

Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients, drug discovery solutions and India branded pharmaceuticals.

Business segments

Pharmaceuticals
Life Science Ingredients
Drug Discovery & Development Solutions
India Branded Pharmaceuticals

Awards

2012

NDTV Profit Business Leadership Award 2012 for Corporate Social Responsibility. National Quality Excellence Award for best in Class manufacturing presented by Stars of the Industry Group.CII ‘National Award for Excellence in Water Management 2012’ as ‘Water Efficient Unit’ for Gajraula Unit.
Economic Times - Frost & Sullivan India Manufacturing Excellence Gold Award - Process Sector for 2012. I.C.C. Award for Water Resource Management in Chemical Industry for the year 2011.

2013

Jubilant Life Sciences Awarded ‘Excellence Award’ by Export Promotion Bureau.
Jubilant Life Sciences declared winner of ‘Supply Chain Excellence Awards’ at 7th Express, Logistics & Supply Chain Leadership Awards 2013.
Jubilant Life Sciences receives prestigious NDTV Profit Business Leadership Award 2012 for Corporate ‘Social Responsibility’.

2014

Jubilant Life Sciences wins Excellence Awards at ‘India Pharma Awards’ 2014.
BRI Partners with Jubilant Life Sciences to Bring XylamaxTM to the South Asia Poultry Market.
Jubilant Life Sciences conferred with Golden Peacock Business Excellence Award-2014.
Jubilant Biosys and Orion Corporation Announces Unique Collaborative Discovery Program in Pain Management Area.
IDRI and Jubilant Chemsys Extend Research for TB Drug Discovery.
Jubilant Life Sciences declared winner of 'Bio Excellence Award 2014' at Bangalore India Bio 2014.
Jubilant Biosys Announces Expansion of Drug Discovery Alliance with Janssen Pharmaceutical.

2015

Jubilant Life Sciences conferred with Golden Peacock National Quality Award.
Jubilant Life Sciences wins ASSOCHAM’s ‘Responsible Organization Excellence’ Award 2014-15.

2016

Sustainability Award for Best Green Process in ‘Chemical Sector’ by ‘FICCI Chemicals & Petrochemicals Awards, 2016’.
Winner of two CHEMEXCIL Export Awards: Trishul Export Award 2012-13 and Gold Export Award 2011-12.
16th Annual Greentech Environment Award 2015 (Gold Category), conferred under ‘Chemicals and Pharmaceutical sector’ - Gajraula plant, India.

2017

Social Entrepreneur of the Year (SEOY)-India Award 2017.
Finalists for Social Entrepreneur of the Year (SEOY) India 2017 Award.
‘Second Awards’ under the category of Basic Inorganic, Organic Chemicals including Agro Chemicals for the outstanding export performance of the year 2015-16 by CHEMEXCIL.